Treatment of crusted sarcoptic mange with fluralaner in a dog

Quilling, Laura L.; Lam, Andrea; Outerbridge, Catherine A.; White, Stephen D.

doi:10.1002/vrc2.109

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of fluralaner has been successfully assessed in dogs with sarcoptic mange. [6][7][8] This antiparasitic drug also has been shown recently to be effective against both psoroptic and sarcoptic mange in pet rabbits. 9,10 In those studies, a single oral dose of fluralaner, at a dosage of 25 mg/kg, was safely administered and effectively controlled both parasitic infestations over a three-month period.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of a spot‐on combination of fluralaner plus moxidectin against naturally acquired Sarcoptes scabiei infestation in 10 pet rabbits: Retrospective case series

d’Ovidio¹,

Santoro

2022

Veterinary Dermatology

View full text Add to dashboard Cite

Background Current treatments for sarcoptic mange in rabbits mainly include administration of avermectines every 10–30 days. Recently, a single oral dose of fluralaner has been shown to be effective to treat sarcoptic mange in 12 pet rabbits over a three‐month period. Objectives To retrospectively assess the efficacy of a spot‐on combination of fluralaner plus moxidectin (Bravecto Plus) for the treatment of sarcoptic mange in rabbits. Animals Ten client‐owned rabbits diagnosed with sarcoptic mange. Materials and Methods An application of fluralaner plus moxidectin at an average dose of 25 mg/kg and 1.24 mg/kg, respectively, was administered topically once. Parasitological and dermatological examination was carried out weekly for one month and monthly for three months. Results The median age at diagnosis was 15 (range 3–48) months. Based on the age of onset, there were three juvenile (<6‐month‐old) and seven adult‐onset cases. Of those, four were generalized (head, feet and/or genital area) and six were localized form (head only). The combination of fluralaner plus moxidectin resulted in 100% eradication of mites and complete resolution of all skin lesions within 21 days. Recurrence was not observed 90 days post‐treatment. Relapse was not observed in one case followed up for a further four months and two rabbits followed up for a further six months. The other pets were lost to follow‐up. Conclusions and Clinical Relevance These results indicated that a single dose of a formulation containing fluralaner plus moxidectin, at 25 mg/kg and 1.24 mg/kg, respectively, was effective for the treatment of naturally occurring sarcoptic mange in rabbits.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Fluralaner is an isoxazoline insecticidal and acaricidal systemic drug that provides long‐acting efficacy after oral administration to dogs. The effectiveness of fluralaner has been successfully assessed in dogs with sarcoptic mange 6–8 …”

Section: Introductionmentioning

confidence: 99%

Efficacy of a spot‐on combination of fluralaner plus moxidectin against naturally acquired Sarcoptes scabiei infestation in 10 pet rabbits: Retrospective case series

d’Ovidio¹,

Santoro

2022

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

Adaptive interventions for advancing in situ wildlife disease management

Wilkinson,

Richards,

Burgess

et al. 2024

Ecological Applications

View full text Add to dashboard Cite

There is a critical need for advancements in disease management strategies for wildlife, but free‐living animals pose numerous challenges that can hinder progress. Most disease management attempts involve fixed interventions accompanied by post hoc outcome assessments focused on success or failure. Though these approaches have led to valuable management advances, there are limitations to both the rate of advancement and amount of information that can be gained. As such, strategies that support more rapid progress are required. Sarcoptic mange, caused by epidermal infection with Sarcoptes scabiei mites, is a globally emerging and re‐emerging panzootic that exemplifies this problem. The bare‐nosed wombat (Vombatus ursinus), a marsupial endemic to southeastern Australia, is impacted by sarcoptic mange throughout its geographic range and enhanced disease management capabilities are needed to improve upon existing in situ methods. We sought to advance in situ wildlife disease management for sarcoptic mange in free‐living bare‐nosed wombats, implementing an adaptive approach using fluralaner (Bravecto, MSD Animal Health) and a structured process of learning and method‐optimisation. By using surveillance of treated wombats to inform real‐time management changes, we have demonstrated the efficacy of topically administered fluralaner at 45 and 85 mg/kg against sarcoptic mange. Importantly, we observed variation in the effects of 45 mg/kg doses, but through our adaptive approach found that 85 mg/kg doses consistently reduced mange severity. Through modifying our surveillance program, we also identified individual‐level variation in wombat observability and used this to quantify the level of surveillance needed to assess long‐term management success. Our adaptive intervention represents the first report of sarcoptic mange management with fluralaner in free‐living wildlife and evaluation of its efficacy in situ. This study illustrates how adapting interventions in real time can advance wildlife disease management and may be applicable to accelerating in situ improvements for other host–pathogen systems.

show abstract

Treatment of crusted sarcoptic mange with fluralaner in a dog

Cited by 2 publications

References 26 publications

Efficacy of a spot‐on combination of fluralaner plus moxidectin against naturally acquired Sarcoptes scabiei infestation in 10 pet rabbits: Retrospective case series

Efficacy of a spot‐on combination of fluralaner plus moxidectin against naturally acquired Sarcoptes scabiei infestation in 10 pet rabbits: Retrospective case series

Adaptive interventions for advancing in situ wildlife disease management

Contact Info

Product

Resources

About